Open AccessPostprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry
Author(s) -
Takehiro Katahira,
Akio Kanazawa,
Mai Shinohara,
Mami Koshibu,
Hideyoshi Kaga,
Tomoya Mita,
Yuka Tosaka,
Koji Komiya,
Takeshi Miyatsuka,
Fuki Ikeda,
Kosuke Azuma,
Naoko Takayanagi,
Takeshi Ogihara,
Chie Ohmura,
Atsushi Miyachi,
Eri Mieno,
Satoko Yamashita,
Hirotaka Watada
Publication year - 2018
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/js.2018-00142
Subject(s) - postprandial , glucagon , dipeptidyl peptidase 4 inhibitor , medicine , glucagon like peptide 1 , context (archaeology) , endocrinology , diabetes mellitus , chemistry , immunoassay , area under the curve , insulin , type 2 diabetes , dipeptidyl peptidase , type 1 diabetes , dipeptidyl peptidase 4 , enzyme , biochemistry , immunology , biology , antibody , paleontology
Context Accurate glucagon level measurements are necessary for investigation of mechanisms for postprandial hyperglycemia in type 2 diabetes. Objective To evaluate the accuracy of postprandial glucagon level measurements using a sandwich ELISA vs a recently established liquid chromatography-high resolution mass spectrometry (LC-HRMS) method in type 2 diabetes mellitus. Design and Participants Twenty patients with type 2 diabetes treated with insulin underwent a meal test before and after administration of the dipeptidyl peptidase-4 inhibitor anagliptin for 4 weeks. Blood samples were taken serially after the meal, and glucagon levels were measured using both ELISA and LC-HRMS. We compared the change from baseline to 4 weeks (Δ0–4W) using the area under the curve for plasma glucagon during the meal test [area under the curve (AUC)0–3h] measured using ELISA and LC-HRMS. Results ELISA-based glucagon AUC0–3h was higher than LC-HRMS–based AUC0–3h at baseline and 4 weeks. However, differences in Δ0–4W-AUC0–3h measured using ELISA and LC-HRMS were not statistically significant. Additionally, Δ0–4W-AUC0–3h measured using ELISA and LC-HRMS were strongly correlated (r = 0.87, P < 0.001). Conclusions Plasma glucagon levels during a meal test in patients with type 2 diabetes measured using ELISA were consistently higher than those measured using LC-HRMS. However, given that the changes in glucagon levels measured using ELISA before and after dipeptidyl peptidase-4 inhibitor therapy were similar to those based on LC-HRMS, this ELISA seems to be useful for evaluating the effect of the drug interventions on postprandial glucagon levels.